Immunization results from the production of antibodies which attack the harmful agent, using the body's own defenses to remove the threat. In an earlier immunization study, 6 percent of the subjects developed acute meningoencephalitis, most likely caused by autoimmune T-cell activation. This caused the trial to be stopped. By developing vaccines that can minimize this T-cell activation while retaining the production of A-antibodies, a safer treatment might result.
The researchers attached A DNA to an adeno-associated virus vector and administered this vaccine to mice orally. Not only were the A levels decreased, but the T-cell immune response was significantly reduced. A single dose of this vaccine enhanced the production of A-antibodies for more than 6 months. Immunohistochemistry of the mouse brain tissue showed that the extra-cellular amyloid deposits were clearly decreased compared to the non-treated mouse.
Hideo Hara, M.D, writes "This new oral vaccine does not induce strong T cell immune reactions, and hence it could reduce the side effect of such meningoencephalitisThis new therapy seems to be effective for prevention and treatment of Alzheimer's disease."
The article is "Development of a safe oral A vaccine using recombinant adeno-associated virus vector for Alzheimer's disease" by Hideo Hara, Alon Monsonego, Katsutoshi Yuasa, Kayo Adachi, Xiao Xiao,
Contact: George Perry, Ph.D.
Case Western Reserve University